Friday, October 23, 2026

USD/EUR Over 2% Down In The Last 21 Sessions

ViaNews Editorial Team

December 1, 2023

USD/EUR Over 2% Down In The Last 21 Sessions

(VIANEWS) - USD/EUR (USDEUR) has been up by 2.71% for the last 21 sessions. At 17:09 EST on Friday, 1 December, USD/EUR (USDEUR) is $0.92.

USD/EUR's yearly highs and lows, it's 3.608% up from its 52-week low and 4.121% down from its 52-week high.

Volatility

USD/EUR's last week, last month's, and last quarter's current intraday variation average was a negative 0.15%, a negative 0.18%, and a positive 0.31%, respectively.

USD/EUR's highest amplitude of average volatility was 0.30% (last week), 0.36% (last month), and 0.31% (last quarter), respectively.

News about

  • According to FXStreet on Thursday, 30 November, "At the time of writing, the EUR/USD is dropping 0.05% on the day to trade at 1.0971."
  • Eur/usd price analysis: holds positive ground above 1.1000, bull cross eyed. According to FXStreet on Wednesday, 29 November, "If a decisive crossover occurs on the daily chart, it would validate a Bull Cross, highlighting that the path of least resistance for EUR/USD is to the upside. ", " From the technical perspective, the bullish outlook of the EUR/USD pair remains intact as the pair holds above the 50- and 100-hour Exponential Moving Averages (EMA) on the daily chart. "
  • Eur/usd slipping back as the 1.1000 handle begins to look more like a ceiling that a goal. According to FXStreet on Wednesday, 29 November, "The EUR/USD captured the 1.1000 major handle on Tuesday, but Euro (EUR) bidders couldn't maintain bullish momentum against the US Dollar (USD), and the pair fell back below the major handle to churn between 1.0990 and 1.0960 in Wednesday's trading session.", "With the 50-day SMA still drifting on the low side of the 200-day SMA, a bullish crossover of the two moving averages will go a long way towards providing technical support for a sustained move higher, though the EUR/USD may need to fall back into the 1.0850 region to kick that off."
  • Eur/usd price analysis: the key contention level is seen at 1.0930. According to FXStreet on Thursday, 30 November, "Additionally, the Relative Strength Index (RSI) stands in bullish territory above 50, indicating the path of least resistance for EUR/USD is to the upside. ", "The EUR/USD pair trades with modest intraday losses during the early European session on Thursday. "
  • Eur/usd: 1.0965-1.1065 could well be the holding pattern into Thursday's US PCE inflation data – ING. According to FXStreet on Wednesday, 29 November, "Unless we see massive upside revisions to 3Q23 US GDP data today, we doubt EUR/USD needs to come a lot lower."

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Crunch: Late-Stage Readouts and Regulatory Milestones Converge on the Ivonescimab PDUFA Date
October 2026 is dense with clinical and regulatory news. Phase 3 trials hit primary endpoints (ALOFT-IPF, RESTORE-3), long-term data came out (MIUDELLA at 6 years, QUILT-3.032), and the FDA accepted Roche's vamikibart BLA. Scholar Rock resubmitted its apitegromab MAA to the EMA. The next catalysts are ESMO 2026 (Oct 23) and the Nov 14 FDA PDUFA date for ivonescimab, followed by Maritime-1 primary completion in January 2027. The speculative QAIAx items (QIII pilot, microcities patent) are a weak, tangential thread with little financial substance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,426 source documents archived
Query this data → isubstrate.com